Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Prescription Drug Pricing: Cost & Control Concerns

Prescription Drug Pricing: Cost & Control Concerns

9781613246399
573.24 zł
515.91 zł Save 57.33 zł Tax included
Lowest price within 30 days before promotion: 515.91 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
The growing cost of brand-name prescription drugs can be a burden on patients, payers and providers of health care, particularly when price increases are large and occur suddenly. Controlling rising prescription drug prices helps to ensure that patients can afford medically necessary and sometimes life-saving medication, and to moderate costs for hospitals and third-party payers such as insurance plans and state and federal governments. This book examines prescription drug pricing costs and control concerns with a focus on extraordinary price increases for brand-name prescription drugs, as well as the characteristics and factors that contributed to this price increase.
Product Details
Nova Science Publishers Inc
73300
9781613246399
9781613246399

Data sheet

Publication date
2012
Issue number
1
Cover
hard cover
Pages count
147
Dimensions (mm)
230.00 x 155.00
Weight (g)
380
  • Preface; Prescription Drugs:: Trends in Usual & Customary Prices for Commonly Used Drugs; Lack of Therapeutically Equivalent Drugs & Limited Competition May Contribute to Extraordinary Price Increases; Overview of Approaches to Control Prescription Drug Spending in Federal Programs; Opening Statement of U.S. Senator Amy Klobuchar, Hearing on At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry; Statement of Senator Charles E Schumer, Chairman, Joint Economic Committee, Hearing on At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry; Statement of Madeline M Carpinelli, Stephen W Schondelmeyer, PRIME Institute, College of Pharmacy, University of Minnesota, Before the Joint Economic Committee, Hearing on Extraordinary Price Increases in the Pharmaceutical Market; Testimony of Alan L Goldbloom, MD, President & CEO, Childrens Hospitals & Clinics of Minnesota, before the Joint Economic Committee, Hearing on At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry; Testimony of Danielle Foltz, before the Joint Economic Committee, Hearing on At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry; Entry Threats & Pricing in the Generic Drug Industry; Index.
Comments (0)
Viewed products

  • Frequently purchased together

    No products available